Citations

Clear

6274 citation(s) found for "To, Andrew".

Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells
Aboulnasr, Fatma, Krogman, Ashton , Graham, Rondell P. , Garcia-Rivera, Enrique , Anderson, J. , Natesampillai, Sekar, Kogan, Nicole , Aravamudan, Murali, Nie, Zilin , Chung, Thomas D.Y. , Buick, Richard, King, Rebecca L. , Novak, Anne J. , Ansell, Stephen M. , Badley, Andrew D. , Misra, Anisha , Garcia-Rivera, Enrique , Anderson, Jeff R , Kogan, Nicole , Graham, Rondell P , Badley, Andrew D , Cummins, Nathan W. , Feldman, Andrew L. , Kenderian, Saad S.

Mayo Clinic

Clinical Cancer Research | July 15, 2020 | Volume: 26 | Issue: 21 | Pages: 5759-5771

10.1158/1078-0432.ccr-20-0251 | PMID 32669373 Get It

Abstract Purpose: TNF-related apoptosis inducing ligand (TRAIL) expression by immune cells contributes to antitumor immunity. A naturally occurring splice variant of TRAIL, called TRAILshort, antagonizes TRAIL-dependent cell killing. It is unknown whether tumor cells express TRAILshort and if it impacts antitumor immunity. Experimental Design: We used an unbiased informatics approach to identify TRAILshort expression in primary human cancers, and validated those results with IHC and ISH. TRAILshort-specific mAbs were used to determine the effect of TRAILshort on tumor cell sensitivity to TRAIL, and to immune effector cell dependent killing of autologous primary tumors. Results: As many as 40% of primary human tumors express TRAILshort by both RNA sequencing and IHC analysis. By ISH, TRAILshort expression is present in tumor cells and not bystander cells. TRAILshort inhibition enhances cancer cell lines sensitivity to TRAIL-dependent killing both in vitro and in immunodeficient xenograft mouse models. Immune effector cells isolated from patients with B-cell malignancies killed more autologous tumor cells in the presence compared with the absence of TRAILshort antibody (P < 0.05). Conclusions: These results identify TRAILshort in primary human malignancies, and suggest that TRAILshort blockade can augment the effector function of autologous immune effector cells. See related commentary by de Miguel and Pardo, p. 5546
Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation
Eswarakumar, Abigail S. , Nina, S. , Ward, Leanne M. , Wasserman, Halley , DiMeglio, Linda A. , Gagné, Julie, Cody, Declan, Zimakas, Paul, Topor, Lisa Swartz , Agrawal, Sungeeta , Calabria, Andrew C. , Tebben, Peter J. , Faircloth, Ruth, Gordon, Rebecca J. , Casey, Linda , Tebben, Peter, Carpenter, Thomas O , DiMeglio, Linda , Tebben, Peter , Backeljauw, Philippe Ferdinand , Weber, David R. , Imel, Erik Allen

Mayo Clinic

Clinical Pediatrics | July 15, 2020 | Volume: 59 | Issue: 12 | Pages: 1080-1085

10.1177/0009922820941097 | PMID 32666808 Get It

In this article, we describe the long-term outcomes of children who were previously reported to have developed hypophosphatemic bone disease in association with elemental formula use. An extended chart review allowed for an updated report of 34 children with regard to severity/duration of bone disease, extent of recovery, and time to correction using radiology reports and biochemical data. After implementation of formula change and/or phosphate supplementation, we found that serum phosphorus concentration increased and serum alkaline phosphatase activity decreased in all patients, normalizing by 6.6 ± 4.0 (mean ± SD) months following diagnosis. The decrease in serum alkaline phosphatase from diagnosis to the time of correction was moderately correlated with the concurrent increase in serum phosphorus ( R = 0.48, P < .05). Age at diagnosis significantly correlated with time to resolution ( R = 0.51, P = .01). This study supports the earlier report that bone disease associated with hypophosphatemia during elemental formula use responds to formula change and/or phosphate supplementation.
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors
Hálfdánarson, Þorvarður R. , Tang, Laura , Bellizzi, Andrew M. , Bergsland, Emily K. , Halperin, Daniel M. , Eads, Jennifer R. , Singh, Simron , Metz, David C. , Naraev, Boris G., Reidy‐Lagunes, Diane , Howe, James R. , Pommier, Rodney F. , Menda, Yusuf , Chan, Jennifer A. , Halfdanarson, Thorvardur R , Bellizzi, Andrew M , Howe, James R , Menda, Yusuf , Strosberg, Jonathan , O’Dorisio, Thomas M. , Fishbein, Lauren , Hope, Thomas A. , Salem, Riad

Mayo Clinic

Pancreas | July 14, 2020 | Volume: 49 | Issue: 7 | Pages: 863-881

10.1097/mpa.0000000000001597 | PMID 32675783 Get It

AbstractThis article is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management of pancreatic neuroendocrine tumors from July 19 to 20, 2018. The guidelines panel consisted of medical oncologists, pathologists, gastroenterologists, endocrinologists, and radiologists. The panel reviewed a series of questions regarding the medical management of patients with pancreatic neuroendocrine tumors as well as questions regarding surveillance after resection. The available literature was reviewed for each of the question and panel members voted on controversial topics, and the recommendations were included in a document circulated to all panel members for a final approval.
Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk
Petersen, Paneen S., Schmit, Stephanie L. , Drew, David A. , Berndt, Sonja I. , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Gallinger, Steven , Gruber, Stephen B. , Haile, Robert W. , Harrison, Tabitha A. , Hoffmeister, Michael , Jacobs, Eric J. , Joshi, Amit D. , Li, Li , Lindor, Noralane M. , Martín, Vicente , Maclnnis, Robert J., Moreno, Vı́ctor , Nan, Hongmei , Rennert, Gad , Slattery, Martha L. , Thibodeau, S. N., Weinstein, Stephanie J. , Woods, Michael O. , Peters, Ulrike , Brenner, Hermann , Rennert, Gad , Drew, David A , Brenner, Hermann , Gruber, Stephen B , Haile, Robert W , Harrison, Tabitha A , Hoffmeister, Michael , Martín, Vicente , Milne, Roger L , Maclnnis, Robert , Moreno, Victor , Potter, John D , Rennert, Gad , Slattery, Martha L , Thibodeau, Steve N, Weinstein, Stephanie J , Rennert, Gad , Brenner, Hermann , Nan, Hongmei , Wang, Xiaoliang , Su, Yu-Ru , Bien, Stephanie A. , Albanes, Demetrius , Campbell, Peter T. , Jenkins, Mark A. , Lin, Yi , Marchand, Loı̈c Le , Milne, Roger L. , Newcomb, Polly A. , Potter, John D. , Chan, Andrew T. , White, Emily , Hsu, Li

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 10, 2020 | Volume: 29 | Issue: 9 | Pages: 1800-1808

10.1158/1055-9965.epi-19-1018 | PMID 32651213 Get It

Abstract Background: Regular use of nonsteroidal anti-inflammatory drugs (NSAID) is associated with lower risk of colorectal cancer. Genome-wide interaction analysis on single variants (G × E) has identified several SNPs that may interact with NSAIDs to confer colorectal cancer risk, but variations in gene expression levels may also modify the effect of NSAID use. Therefore, we tested interactions between NSAID use and predicted gene expression levels in relation to colorectal cancer risk. Methods: Genetically predicted gene expressions were tested for interaction with NSAID use on colorectal cancer risk among 19,258 colorectal cancer cases and 18,597 controls from 21 observational studies. A Mixed Score Test for Interactions (MiSTi) approach was used to jointly assess G × E effects which are modeled via fixed interaction effects of the weighted burden within each gene set (burden) and residual G × E effects (variance). A false discovery rate (FDR) at 0.2 was applied to correct for multiple testing. Results: Among the 4,840 genes tested, genetically predicted expression levels of four genes modified the effect of any NSAID use on colorectal cancer risk, including DPP10 (PG×E = 1.96 × 10−4), KRT16 (PG×E = 2.3 × 10−4), CD14 (PG×E = 9.38 × 10−4), and CYP27A1 (PG×E = 1.44 × 10−3). There was a significant interaction between expression level of RP11-89N17 and regular use of aspirin only on colorectal cancer risk (PG×E = 3.23 × 10−5). No interactions were observed between predicted gene expression and nonaspirin NSAID use at FDR &lt; 0.2. Conclusions: By incorporating functional information, we discovered several novel genes that interacted with NSAID use. Impact: These findings provide preliminary support that could help understand the chemopreventive mechanisms of NSAIDs on colorectal cancer.
Dietary Intake Is Associated With Ankle-brachial Index, Inflammation, And Ambulation In Peripheral Artery Disease Patients
Montgomery, Polly S., Palacios, Fedrico Silva-, Knehans, Allen, Wang, Ming , Shen, Biyi , Casanegra, Ana I. , Gardner, Andrew W.

Mayo Clinic

Medicine & Science in Sports & Exercise | July 9, 2020 | Volume: 52 | Issue: 7S | Pages: 1074-1074

10.1249/01.mss.0000687316.54687.03 Get It

Relationships Between Sport Nutrition Knowledge, Body Composition And Body Weight Goal In Female Soccer Players.
Shafer, A., Paisley, Jordan, Askow, Andrew T. , Luedke, Joel, Nolte, Charles, Erickson, Jacob L. , Askow, Andrew T , Jagim, Andrew R. , Shafer, Alexis

Mayo Clinic

Medicine & Science in Sports & Exercise | July 9, 2020 | Volume: 52 | Issue: 7S | Pages: 873-873

10.1249/01.mss.0000685016.62836.28 Get It

Recovery Of Heart Rate Variability And Hemodynamics After Heated Exercise In Active Females
Zabriskie, Hannah A. , Kerksick, Chad M. , Jagim, Andrew R.

Mayo Clinic

Medicine & Science in Sports & Exercise | July 9, 2020 | Volume: 52 | Issue: 7S | Pages: 853-853

10.1249/01.mss.0000684756.54339.d7 Get It

Comparison Of Energy Expenditure Observed Between Scheduled Activities In Female Collegiate Basketball And Lacrosse Athletes
Zanders, Bre R., Stecker, Richard A., Moon, Jessica M. , Zabriskie, Hannah A. , Zanders, Breyannah R., Harty, Patrick S. , Currier, Brad S. , Mumford, Petey W. , Jagim, Andrew R. , Kerksick, Chad M.

Mayo Clinic

Medicine & Science in Sports & Exercise | July 9, 2020 | Volume: 52 | Issue: 7S | Pages: 599-600

10.1249/01.mss.0000680772.22401.21 Get It

Triage of patients with venous and lymphatic diseases during the COVID-19 pandemic – The Venous and Lymphatic Triage and Acuity Scale (VELTAS)
Parsi, Kurosh , Rij, André M. van , Meissner, Mark H. , Gloviczki, Péter , Benson, Stephen, Bottini, Oscar, Canata, Victor , Dinnen, Paul, Gasparis, Antonios, Gianesini, Sergio , Lal, Brajesh K. , Kabnick, Lowell S , Marston, William A. , Granados, Alberto Martinez, Morrison, Nick , Paraskevas, P, Patel, Malay , Roberts, Stefania , Komlos, Pedro, Varghese, Roy , Welch, Harold J. , Wittens, Cees H.A. , Parsi, Kurosh , Davies, Alun H. , Maeseneer, Marianne De , Huber, David, Jenkins, David, Lim, Adrian, Nicolaides, Andrew , Rogan, Christopher , Schul, Marlin W. , Stirling, Andy , Thibault, Simon , Gloviczki, Péter

Mayo Clinic

Phlebology: The Journal of Venous Disease | July 8, 2020 | Volume: 35 | Issue: 8 | Pages: 550-555

10.1177/0268355520930884 | PMID 32639862 Get It

The coronavirus disease 2019 (COVID-19) global pandemic has resulted in diversion of healthcare resources to the management of patients infected with SARS-CoV-2 virus. Elective interventions and surgical procedures in most countries have been postponed and operating room resources have been diverted to manage the pandemic. The Venous and Lymphatic Triage and Acuity Scale was developed to provide an international standard to rationalise and harmonise the management of patients with venous and lymphatic disorders or vascular anomalies. Triage urgency was determined based on clinical assessment of urgency with which a patient would require medical treatment or surgical intervention. Clinical conditions were classified into six categories of: (1) venous thromboembolism (VTE), (2) chronic venous disease, (3) vascular anomalies, (4) venous trauma, (5) venous compression and (6) lymphatic disease. Triage urgency was categorised into four groups and individual conditions were allocated to each class of triage. These included (1) medical emergencies (requiring immediate attendance), example massive pulmonary embolism; (2) urgent (to be seen as soon as possible), example deep vein thrombosis; (3) semi-urgent (to be attended to within 30–90 days), example highly symptomatic chronic venous disease, and (4) discretionary/non-urgent- (to be seen within 6–12 months), example chronic lymphoedema. Venous and Lymphatic Triage and Acuity Scale aims to standardise the triage of patients with venous and lymphatic disease or vascular anomalies by providing an international consensus-based classification of clinical categories and triage urgency. The scale may be used during pandemics such as the current COVID-19 crisis but may also be used as a general framework to classify urgency of the listed conditions.